Health
FDA approves first treatment for a rare genetic disorder – News-Medical.Net
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.
Reviewed by Emily Henderson, B.Sc.Nov 23 2020
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input…
-
General21 hours agoGather Round’s first ever Sicko Saturday treats Adelaide Oval to a day of gloriously bad football
-
General21 hours agoTrump’s trade team chases 90 deals in 90 days
-
General21 hours agoClick-bait Bandt | The Spectator Australia
-
General19 hours agoUS exempts smartphones, computers and other electronics from Donald Trump’s reciprocal tariffs